SCHEMBL1336985

SCHEMBL1336985

Cn1c(=O)c(-c2ccc(F)cc2)cc2c3cc(-c4cc[nH]n4)ccc3n(C)c21

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK14 Q16539 6/20 0.37
▸ GABRA1 P14867 1/20 0.32
▸ GABRG2 P18507 1/20 0.32
▸ GABRB3 P28472 1/20 0.32
▸ GABRA5 P31644 1/20 0.32
▸ GABRA3 P34903 1/20 0.32
▸ GABRA2 P47869 1/20 0.32
▸ BRD4 O60885 1/20 0.32
▸ CYP3A4 P08684 1/20 0.32
▸ JAK2 O60674 2/20 0.32
▸ MAPK13 O15264 1/20 0.31
▸ MAPK12 P53778 1/20 0.31
▸ MAPK11 Q15759 1/20 0.31
▸ PIK3CA P42336 1/20 0.31
▸ PRMT5 O14744 1/20 0.31
▸ WDR77 Q9BQA1 1/20 0.31
▸ CDC7 O00311 1/20 0.31
▸ PIM1 P11309 1/20 0.31
▸ GSK3B P49841 1/20 0.31
▸ HIPK2 Q9H2X6 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4762650 0.89 CYP3A4 (0.34) GABRA1GABRG2GABRB3GABRA5CYP3A4
SCHEMBL1339349 0.81 KDM4E (0.36) MAPK14GABRA1KDM4E
SCHEMBL4761976 0.80 KDM4E (0.35) MAPK14GABRA1GABRG2GABRB3GABRA5
SCHEMBL1336944 0.80 MAPK14 (0.36) MAPK14GABRA1GABRG2GABRB3GABRA5
SCHEMBL1338829 0.79 ALDH1A1 (0.47) MAPK14GABRA1GABRG2GABRB3GABRA5
SCHEMBL1338537 0.78 L3MBTL1 (0.44) MAPK14GABRA1GABRG2GABRB3GABRA5
SCHEMBL1340490 0.78 DRD2 (0.36) MAPK14GABRA1GABRG2GABRB3GABRA5
SCHEMBL1339090 0.78 DRD2 (0.35) MAPK14CYP3A4PIK3CAGSK3BKDM4E
SCHEMBL1339069 0.78 GABRA1 (0.36) MAPK14GABRA1GABRG2GABRB3GABRA5
SCHEMBL1339171 0.77 KDM4E (0.35) MAPK14GABRA1GABRG2GABRB3GABRA5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063061-B2 6-(2-amino-1,3-thiazol-4-yl)-3-(2,4-dichlorophenyl)-1-methyl-1,9-dihydro-2H-pyrido[2,3-b]indol-2-one; affinity for GABAA-receptor-associated omega modulatory sites SANOFI-AVENTIS (FR) 2011-11-22 — — US disclosed
EP-1940840-B1 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2010-07-21 — — EP disclosed
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof SANOFI-AVENTIS (FR) 2008-10-23 — — US disclosed
EP-1940840-A1 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF Sanofi-Aventis (FR) 2008-07-09 — — EP disclosed
WO-2007045758-A1 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2007-04-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof CYP11B2, CYP11B1, CYP2D6 MAPK14 3487/4885GABRA1 1457/4885GABRG2 1617/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback